The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)

Real-world comparison between 6 weeks versus 3 weeks adjuvant pembrolizumab in high-risk stage IIB-IIID cutaneous malignant melanoma: Experience from an academic cancer center.

Manan  Shah

No Relationships to Disclose

Saba  Shafi

No Relationships to Disclose

Kari Lynn  Kendra

Research Funding - Array BioPharma (Inst); Bristol-Myers Squibb (Inst); Checkmate Pharmaceuticals (Inst); GlaxoSmithKline (Inst); Idera (Inst); Immunocore (Inst); Isarti Oncology (Inst); Merck (Inst); Novartis (Inst)

Claire F.  Verschraegen

Consulting or Advisory Role - CTI

Richard Cheng Han  Wu

Research Funding - Iovance Biotherapeutics (Inst); Regeneron (Inst); Xilio Therapeutics (Inst)